Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: A prospective, randomized, single-blind, placebo-controlled clinical trial

Human Reproduction

Volumn 17, Issue 12, 2002, Pages 3213-3219

  Palomba, Stefano ^a   Russo, Tiziana ^a   Orio Jr , Francesco ^b   Tauchmanovà, Libuse ^b   Zupi, Errico ^c   Panici, Pier Luigi Benedetti ^d   Nappi, Carmine ^b   Colao, Annamaria ^b   Lombardi, Gaetano ^b   Zullo, Fulvio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Add back therapy; Fibroids; GnRH analogue; Leiomyomas; Raloxifene

Indexed keywords

GONADORELIN DERIVATIVE; LEUPRORELIN; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ABDOMINAL PRESSURE; ADD ON THERAPY; ADULT; ARTICLE; CANCER SIZE; CLINICAL TRIAL; COMPUTER SYSTEM; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LEIOMYOMA; MAJOR CLINICAL STUDY; MENORRHAGIA; PELVIS PAIN SYNDROME; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SYMPTOM; TUMOR CLASSIFICATION; URINARY FREQUENCY; DELAYED RELEASE FORMULATION; ECHOGRAPHY; HOT FLUSH; PAIN; PATIENT; UTERUS CANCER;

DELAYED-ACTION PREPARATIONS; FEMALE; HOT FLASHES; HUMANS; LEIOMYOMA; LEUPROLIDE; MENORRHAGIA; PAIN; PATIENT DROPOUTS; PLACEBOS; PREMENOPAUSE; PROSPECTIVE STUDIES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; UTERINE NEOPLASMS;

EID: 0036904277     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/17.12.3213     Document Type: Article

References (48)

1. Adashi, E.Y. (1994) Long-term gonadotrophin releasing hormone agonist therapy: The evolving issue of steroidal 'add-back' paradigms. Hum. Reprod., 9, 1380-1397.
2. Barbieri, R.L. (1997) Reduction in the size of a uterine leiomyoma following discontinuation of an estrogen-progestin contraceptive. Gynecol. Obstet. Invest., 43, 276-277.
3. Barrett-Connor, E., Grady, D., Sashegyi, A., Anderson, P.W., Cox, D.A., Hoszowski, K., Rautaharju, P., Harper, K.D. and The MORE Investigators (Multiple Outcomes of Raloxifene Evaluation) (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. J. Am. Med. Assoc., 287, 847-857.
4. Black, L.J., Sato, M., Rowley, E.R., Magee, D.E., Bekele, A., Williams, D.C., Cullinan, G.J., Bendele, R., Kauffman, R.F. and Bensch, W.R. (1994) Raloxifene (LY139481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest., 93, 63-69.
5. Brandon, D.D., Erickson, T.E., Keenan, E.J., Strawn, E.Y., Novy, M.J., Burry, K.A., Warner, C. and Clinton, G.M. (1995) Estrogen receptor gene expression in human uterine leiomyomata. J. Clin. Endocrinol. Metab., 80, 1876-1881.
6. Bryant, H.U., Glasebrook, A.L., Yang, N.N. and Sato, M. (1996) A pharmacological review of raloxifene. J. Bone Miner. Metab., 14, 1-9.
7. Carr, B.R., Marshburn, P.B., Weatherall, P.T., Bradshaw, K.D., Breslau, N.A., Byrd, W., Roark, M. and Steinkampf, M.P. (1993) An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: A prospective, randomized, double blind, placebo-controlled, crossover trial. J. Clin. Endocrinol. Metab., 76, 1217-1223.
8. Cohen, F.J., Watts, S., Shah, A., Akers, R. and Plouffe, L. (2000) Uterine effects of 3-years raloxifene therapy on postmenopausal women younger than age 60. Obstet. Gynecol., 95, 104-110.
9. Coutinho, E.M. (1989) Gestrinone in the treatment of myomas. Acta Obstet. Gynecol. Scand., 150, 39-46.
10. Coutinho, E.M. and Goncalves, M.T. (1989) Long-term treatment of leiomyomas with gestrinone. Fertil. Steril., 51, 939-946.
11. Cummings, S.R., Eckert, S., Krueger, K.A., Grady, D., Powles, T.J., Cauley, J.A., Norton, L., Nickelsen, T., Bjarnason, N.H., Morrow, M. et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J. Am. Med. Assoc., 281, 2189-2197.
12. De Leo, V., La Marca, A. and Morgante, G. (1999) Short-term treatment of uterine fibromyomas with danazol. Gynecol. Obstet. Invest., 47, 258-262.
13. De Leo, V., La Marca, A., Morgante, G., Severi, F.M. and Petraglia, F. (2001) Administration of somatostatin analoue reduces uterine and myoma volume in women with uterine leiomyomata. Obstet. Gynecol., 75, 632-633.
14. Di Carlo, C., Palomba, S., Tommaselli, G.A., Guida, M., Di Spiezio Sardom A. and Nappi, C. (2000) Use of leuprolide acetate plus tibolone in the treatment of the severe premenstrual syndrome. Fertil. Steril., 75, 380-384.
15. Ettinger, B., Black D.M., Mitlak, B.H., Knickerbocker, R.H., Nickelsen, T. and Genant, N.K. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. J. Am. Med. Assoc., 282, 637-645.
16. Filicori, M., Hall, D.A., Loughlin, J.S., Rivier, J., Vale, W. and Crowley, W.F. Jr (1983) A conservative approach to the management of uterine leiomyoma: Pituitary desensibilization by a luteinizing hormone-releasing hormone analogue. Am. J. Obstet. Gynecol., 147, 726-727.
17. Friedman, A.J. and Thomas, P.P. (1999) Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas? Obstet. Gynecol., 85, 631-635.
18. Friedman, A.J., Lobel, S.M., Rein, M.S. and Barbieri, R.L. (1990) Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonist: The estrogen threshold hypothesis. Am. J. Obstet. Gynecol., 163, 1114-1119.
19. Friedman, A.J., Daly, M., Juneau-Norcross, M., Gleason, R., Rein, M.S. and Leboff, M. (1994) Long-term medical therapy for leiomyoma uteri: A prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years. Hum. Reprod., 9, 1618-1625.
20. Fuchs-Young, R., Howe, S., Hale, L., Miles, R. and Walker, C. (1996) Inhibition of estrogen stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Mol. Carcinogen., 17, 151-159.
21. Goldstein, S.R., Scheele, W.H., Rajagopalan, S.K., Wilkie, J.L., Walsh, B.W. and Parsons, A.K. (2000) A 12-month comparative study of raloxifene, estrogen and placebo on the postmenopausal endometrium. Obstet. Gynecol., 95, 95-103.
22. Kertel, L.M., Murphy, A.A., Morales, A.J. and Yen, S.S. (1994) Clinical efficacy of antiprogesterone RU 486 in the treatment of endometriosis and uterine fibroids. Hum. Reprod., 9, 116-120.
23. Khovidhunkit, W. and Shoback, D.M. (1999) Clinical effects of raloxifene hydrochloride in women. Ann. Intern. Med., 130, 431-439.
24. Kuiper, G.G.J.M., Carlsson, B., Grandien, K., Enmark, E., Haggblad, J., Nilsson, S. and Gustafsson, J.A. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology, 138, 863-870.
25. Lessl, M., Klotzbuecher, M., Schoen, S., Reles, A., Stockemann, K. and Fuhrmann, U. (1997) Comparative messenger ribonucleic acid analysis of immediate early genes and sex steroid receptors in human leiomyomas and healthy myometrium. J. Clin. Endocrinol. Metab., 82, 2596-2600.
26. Lumsden, M.A., West, C.P. and Baird, D.T. (1989) Tamoxifen prolongs luteal phase in premenopausal women but has no effect on the size of uterine fibroids. Clin. Endocrinol. (Oxf.) 31, 335-343.
27. Marshall, L.M., Spiegelman, D., Goldman, M.B., Manson, J.E., Colditz, G.A., Barbieri, R.L., Stampfer, M.J. and Hunter, D.J. (1998) A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil. Steril., 70, 432-439.
28. Minakuchi, K., Kawamura, N. and Tsujimura, A. (1999) Remarkable and persistent shrinkage of uterine leiomyoma associated with interferon alfa treatment for hepatitis. Lancet, 353, 2127-2128.
29. Modelska, K. and Cummings, S. (2002) Tibolone for postmenopausal women: Systematic review of randomized trials. J. Clin. Endocrinol. Metab., 87, 16-23.
30. Mosca, L. (2001) Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial. Ann. NY Acad. Sci., 949, 181-185.
31. Murphy, A.A., Kettel, L.M., Morales, A.J., Roberts, V.J. and Yen, S.S.C. (1993) Regression of uterine leiomyomata in response to the antiprogesterone RU 486. J. Clin. Endocrinol. Metab., 76, 513-517.
32. Nakayama, H., Yano, T., Sagara, Y., Kikuchi, A., Ando, K., Wang, Y., Watanabe, M., Matsumi, H., Osuga, Y., Momoeda, M. et al. (1999) Estriol add-back therapy in the long acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata. Gynecol. Endocrinol., 13, 382-389.
33. Paech, K., Webb, P., Kuiper, G.G.J.M., Nilsson, S., Gustafsson, J., Kushner, P.J. and Scanlan, T.S. (1997) Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science, 277, 1508-1510.
34. Palomba, S., Affinito, P., Tommaselli, G.A. and Nappi, C. (1998) A clinical trial on the effects of tibolone association with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil. Steril., 70, 111-118.
35. Palomba, S., Affinito, P., Di Carlo, C., Bifulco, G. and Nappi C. (1999) Effects of long-term administration of tibolone plus GnRH-a in the treatment of uterine leiomyomata on effectiveness, vasomotor symptoms, bone mass and lipid profile. Fertil. Steril., 72, 889-895.
36. Palomba, S., Pellicano, M., Affinito, P., Di Carlo, C., Zullo, F. and Nappi, C. (2001a) Effectiveness of short-term administration of tibolone plus gonadotropin-releasing hormone analogue on the surgical outcome of laparoscopic myomectomy. Fertil. Steril., 75, 429-433.
37. Palomba, S., Sammartino, A., Di Carlo, C., Affinito, F. and Nappi, C. (2001b) Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women. Fertil. Steril., 76, 38-43.
38. Palomba, S., Orio, F. Jr, Morelli, M., Russo, T., Pellicano, M., Zupi, E., Lombardi, G., Nappi, C., Benedetti Panici, P.G. and Zullo, F. (2002a) Raloxifene administration in premenopausal women with uterine leiomyomas: A pilot study. J. Clin. Endocrinol. Metab., 87, 3303-3308.
39. Palomba, S., Orio, F. Jr, Di Carlo, C., Colao, A., Sena, T., Lombardi, G., Zullo, F. and Mastrantonio, P. (2002b) Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab., 87, 1502-1508.
40. Palomba, S., Orio, F. Jr, Morelli, M., Russo, T., Pellicano, M., Nappi, C., Mastrantonio, P., Lombardi, G., Colao, A. and Zullo, F. (2002c) Raloxifene administration in women treated with gonadotropin releasing hormone agonist for uterine leiomyomas: Effects on bone metabolism. J. Clin. Endocrinol. Metab., 87, 4476-4481.
41. Pickersgill, A. (1998) GnRH agonists an add-back therapy: Is there a perfect combination? Br. J. Obstet. Gynaecol., 105, 475-485.
42. Porter, K.B., Tsibris, J.C., Porter, G.W., Fuchs-Young, R., Nicosia, S.V. and O'Brien, W.F. (1998) Effects of raloxifene in a guinea pig model for leiomyomas. Am. J. Obstet. Gynecol., 179, 1283-1287.
43. Sadan, O., Ginath, S., Sofer, D., Rotmensch, S., Debby, A., Glezerman, M. and Zakut, H. (2001) The role of tamoxifen in the treatment of symptomatic uterine leiomyomatala pilot study. Eur. J. Obstet. Gynecol. Reprod. Biol., 96, 183-186.
44. Sener, A.B., Seckin, N.C., Ozmen, S., Gokmen, O., Dogu, N. and Ekici, E. (1996) The effect of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil. Steril., 63, 354-357.
45. Steward, E.A. (2001) Uterine fibroids. Lancet, 357, 293-298.
46. Surrey, E.S. (1995) Steroidal and nonsteroidal 'add-back' therapy: Extending safety and efficacy of gonadotropin-releasing hormone agonist in the gynecologic patient. Fertil. Steril., 64, 673-685.
47. Walker, C.L., Burroughs, K.D., Davis, B., Sowell, K., Everitt, J.I. and Fuchs-Young, R. (2000) Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. J. Soc. Gynecol. Invest., 7, 249-256.
48. Walsh, B.W., Kuller, L.H., Wild, R.A., Paul, S., Farmer, M., Lawrence, J.B., Shah, A.S. and Anderson, P.W. (1998) Effect of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J. Am. Med. Assoc., 279, 1445-1451.